Drug Profile
GX 301
Alternative Names: Telomerase peptide cancer vaccine - GenovaxLatest Information Update: 21 Jul 2022
Price :
$50
*
At a glance
- Originator Genovax
- Developer Genovax; Mediolanum
- Class Adjuvants; Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Peptides; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
- Discontinued Renal cancer
Most Recent Events
- 21 Jul 2022 No development reported - Phase-II for Prostate cancer (Hormone refractory, Second-line therapy or greater) in Italy (Intradermal) (NCT02293707)
- 21 Jul 2022 No development reported - Phase-II for Prostate cancer (Hormone refractory, Second-line therapy or greater) in Spain (Intradermal) (NCT02293707)
- 27 Aug 2019 GX 301 is still in phase II trial for Prostate cancer (Hormone-refractory, Second-line therapy or greater) in Italy and Spain (Intradermal) (NCT02293707)